Literature DB >> 22350375

The superiority of conservative resection and adjuvant radiation for craniopharyngiomas.

Adam Schoenfeld1, Melike Pekmezci, Michael J Barnes, Tarik Tihan, Nalin Gupta, Kathleen R Lamborn, Anu Banerjee, Sabine Mueller, Susan Chang, Mitchel S Berger, Daphne Haas-Kogan.   

Abstract

The purpose of this study is to evaluate the roles of resection extent and adjuvant radiation in the treatment of craniopharyngiomas. We reviewed the records of 122 patients ages 11-52 years who received primary treatment for craniopharyngioma between 1980 and 2009 at the University of California, San Francisco (UCSF). Primary endpoints were progression free survival (PFS) and overall survival (OS). Secondary endpoints were development of panhypopituitarism, diabetes insipidus (DI), and visual field defects. Of 122 patients, 30 (24%) were treated with gross total resection (GTR) without radiation therapy (RT), 3 (3%) with GTR + RT, 41 (33.6%) with subtotal resection (STR) without RT, and 48 (39.3%) with STR + RT. Median age at diagnosis was 30 years, with 46 patients 18 years or younger. Median follow-up for all patients was 56.4 months (interquartile range 18.9-144.2 months) and 47 months (interquartile range 12.3-121.8 months) for the 60 patients without progression. Fifty six patients progressed, 10 have died, 6 without progression. Median PFS was 61.1 months for all patients. PFS rate at 2 years was 61.5% (95% CI: 52.1-70.9). OS rate at 10 years was 91.1% (95% CI 84.3-97.9). There was no significant difference in PFS and OS between patients treated with GTR vs. STR + XRT (PFS; p = 0.544, OS; p = 0.735), but STR alone resulted in significantly shortened PFS compared to STR + RT or GTR (p < 0.001 for both). STR was associated with significantly shortened OS compared to STR + RT (p = 0.050) and trended to shorter OS compared to GTR (p = 0.066). GTR was associated with significantly greater risk of developing DI (56.3 vs. 13.3% with STR + XRT, p < 0.001) and panhypopituitarism (54.8 vs. 26.7% with STR + XRT, p = 0.014). In conclusion, for patients with craniopharyngioma, STR + RT may provide superior clinical outcome, achieving better disease control than STR and limiting side effects associated with aggressive surgical resection.

Entities:  

Mesh:

Year:  2012        PMID: 22350375      PMCID: PMC3879154          DOI: 10.1007/s11060-012-0806-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  Craniopharyngioma: a comparison of tumor control with various treatment strategies.

Authors:  Isaac Yang; Michael E Sughrue; Martin J Rutkowski; Rajwant Kaur; Michael E Ivan; Derick Aranda; Igor J Barani; Andrew T Parsa
Journal:  Neurosurg Focus       Date:  2010-04       Impact factor: 4.047

2.  Clinical outcome in children with recurrent craniopharyngioma after primary surgery.

Authors:  J A Kalapurakal; S Goldman; Y C Hsieh; T Tomita; M H Marymont
Journal:  Cancer J       Date:  2000 Nov-Dec       Impact factor: 3.360

3.  20-year experience in childhood craniopharyngioma.

Authors:  S Hetelekidis; P D Barnes; M L Tao; E G Fischer; L Schneider; R M Scott; N J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-30       Impact factor: 7.038

4.  Endocrine and neurologic outcome in childhood craniopharyngioma: Review of effect of treatment in 42 patients.

Authors:  M J Thomsett; F A Conte; S L Kaplan; M M Grumbach
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

5.  Management of childhood craniopharyngioma: can the morbidity of radical surgery be predicted?

Authors:  C J De Vile; D B Grant; B E Kendall; B G Neville; R Stanhope; K E Watkins; R D Hayward
Journal:  J Neurosurg       Date:  1996-07       Impact factor: 5.115

6.  Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma--a 20-year experience.

Authors:  R M Scott; S Hetelekidis; P D Barnes; L Goumnerova; N J Tarbell
Journal:  Pediatr Neurosurg       Date:  1994       Impact factor: 1.162

Review 7.  Neuroimaging of childhood craniopharyngioma.

Authors:  D C Harwood-Nash
Journal:  Pediatr Neurosurg       Date:  1994       Impact factor: 1.162

8.  Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults.

Authors:  Diana C H Stripp; Amit Maity; Anna J Janss; Jean B Belasco; Zelig A Tochner; Joel W Goldwein; Thomas Moshang; Lucy B Rorke; Peter C Phillips; Leslie N Sutton; Hui-Kuo G Shu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

9.  The descriptive epidemiology of craniopharyngioma.

Authors:  G R Bunin; T S Surawicz; P A Witman; S Preston-Martin; F Davis; J M Bruner
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

10.  Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.

Authors:  H L Weiner; J H Wisoff; M E Rosenberg; M J Kupersmith; H Cohen; D Zagzag; T Shiminski-Maher; E S Flamm; F J Epstein; D C Miller
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

View more
  31 in total

1.  Radiotherapy for craniopharyngioma.

Authors:  Ajay Aggarwal; Naomi Fersht; Michael Brada
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

2.  Characteristics and overall survival in pediatric versus adult craniopharyngioma: a population-based study.

Authors:  Brandon M Lehrich; Khodayar Goshtasbi; Frank P K Hsu; Edward C Kuan
Journal:  Childs Nerv Syst       Date:  2021-02-28       Impact factor: 1.475

3.  Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database.

Authors:  Yuan J Rao; Comron Hassanzadeh; Benjamin Fischer-Valuck; Michael R Chicoine; Albert H Kim; Stephanie M Perkins; Jiayi Huang
Journal:  J Neurooncol       Date:  2016-12-23       Impact factor: 4.130

4.  Granular cell tumor of the infundibulum: a systematic review of MR-radiography, pathology, and clinical findings.

Authors:  Jessica B Polasek; Yosef Laviv; Fares Nigim; Rafael Rojas; Matthew Anderson; Hemant Varma; Ekkehard M Kasper
Journal:  J Neurooncol       Date:  2018-08-23       Impact factor: 4.130

5.  Giant craniopharyngiomas in children: short- and long-term implications.

Authors:  Laviv Yosef; Kasper M Ekkehard; Michowitz Shalom
Journal:  Childs Nerv Syst       Date:  2015-11-16       Impact factor: 1.475

6.  Limited utility despite accuracy of the national SEER dataset for the study of craniopharyngioma.

Authors:  Todd C Hankinson; Emma C Fields; Michelle R Torok; Brenda L Beaty; Michael H Handler; Nicholas K Foreman; Brent R O'neill; Arthur K Liu
Journal:  J Neurooncol       Date:  2012-08-23       Impact factor: 4.130

7.  Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity.

Authors:  Andrew J Bishop; Brad Greenfield; Anita Mahajan; Arnold C Paulino; M Fatih Okcu; Pamela K Allen; Murali Chintagumpala; Lisa S Kahalley; Mary F McAleer; Susan L McGovern; William E Whitehead; David R Grosshans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-19       Impact factor: 7.038

8.  Outcome of Chinese children with craniopharyngioma: a 20-year population-based study by the Hong Kong Pediatric Hematology/Oncology Study Group.

Authors:  Anthony Pak-Yin Liu; Joanna Yuet-Ling Tung; Dennis Tak-Loi Ku; Chung-Wing Luk; Alvin Siu-Cheung Ling; Dora Lai-Wan Kwong; Kevin King-Fai Cheng; Wilson Wai-Shing Ho; Matthew Ming-Kong Shing; Godfrey Chi-Fung Chan
Journal:  Childs Nerv Syst       Date:  2020-01-23       Impact factor: 1.475

9.  Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study.

Authors:  Michael S Rutenberg; Ronny L Rotondo; Dinesh Rao; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Christopher G Morris; William M Mendenhall
Journal:  J Neurooncol       Date:  2020-02-21       Impact factor: 4.130

10.  Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

Authors:  Priscilla K Brastianos; Ganesh M Shankar; Corey M Gill; Amaro Taylor-Weiner; Naema Nayyar; David J Panka; Ryan J Sullivan; Dennie T Frederick; Malak Abedalthagafi; Pamela S Jones; Ian F Dunn; Brian V Nahed; Javier M Romero; David N Louis; Gad Getz; Daniel P Cahill; Sandro Santagata; William T Curry; Fred G Barker
Journal:  J Natl Cancer Inst       Date:  2015-10-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.